Clinical trials: GI Disorders
Inflammatory Bowel Diseases
Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function.
The aim of this study was to evaluate the effect of the consumption of yogurt added with bifidobacteria and soluble fiber on gastrointestinal function of healthy adults.
- Trial name
- NCT01173588
- Testing
- yogurt added with bifidobacteria and soluble fiber (YBF)
- Where
- Mexico
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Instituto Lala
Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00215566
- Testing
- DDP733
- Where
- 15 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Dynogen Pharmaceuticals
Gastrointestinal Stromal Tumors
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with metastatic and/or unresectable GIST following…
- Trial name
- NCT00688766
- Testing
- retaspimycin hydrochloride (IPI-504), Best supportive care
- Volunteers
- 47 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Gastro-oesophageal Junction Cancer, Gastric Cancer
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene…
- Trial name
- SHINE (NCT01457846)
- Testing
- AZD4547, paclitaxel
- Where
- 61 sites in Belgium, Bulgaria and 14 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Refractory Metastatic Colorectal Cancer
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.
- Trial name
- NCT07361003
- Testing
- Suvemcitug injection, trifluridine/tipiracil tablets
- Where
- 6 sites in China
- Volunteers
- 464 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Ulcerative Colitis (UC), Healthy Volunteer
Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
PALI-2108 is a new oral medication designed to treat ulcerative colitis (UC) by targeting the intestines. It works as a phosphodiesterase-4 (PDE4) inhibitor prodrug, meaning it becomes active only after being processed by…
- Trial name
- NCT06663605
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Palisade Bio
Dermatitis
A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)
The purpose of this study is to obtain information concerning the safety and effective use of a protective barrier film in patients experiencing severe incontinence associated dermatitis.
- Trial name
- NCT02724449
- Testing
- Cavilon Advanced Barrier Film
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Solventum US LLC
Colorectal Cancer
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with…
- Trial name
- NCT06562543
- Testing
- Fruquintinib
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 78 people
- Sponsor
- Takeda
Ulcerative Colitis (UC)
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had…
- Trial name
- U-ACTIVATE (NCT03006068)
- Testing
- Upadacitinib (ABT-494)
- Where
- 492 sites in United States, Argentina and 44 more
- Volunteers
- 950 people
- Sponsor
- AbbVie
Crohn's Disease
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
- Trial name
- MAPUS (NCT01951326)
- Testing
- RHB-104
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- RedHill Biopharma Limited
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Gastric Cancer, Gastroesophageal Cancer (GC)
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally…
- Trial name
- NCT05632939
- Testing
- ASKB589 +CAPOX+Sintilimab/Tislelizumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- AskGene Pharma, Inc.
Gastrointestinal Stromal Tumors
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST.
- Trial name
- NCT04254939
- Testing
- CS3007 (BLU-285)
- Where
- 16 sites in China
- Volunteers
- 65 people
- Sponsor
- CStone Pharmaceuticals
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
- Trial name
- NCT02307812
- Testing
- Ramucirumab, Paclitaxel
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.